BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SHR-4610 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SHR-4610\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07239596-11113@assetmemo.bio
DTSTAMP:20261121T005558Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:SHR-4610: Phase 1/2 readout est. (NCT07239596)
DESCRIPTION:SHR-4610\, phase 1/2.\nStudy: Phase Ib/II Clinical Study of SHR
 -8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Ca
 rcinom\nEstimated primary completion: December 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/shr-4610#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07239596
URL:https://assetmemo.bio/drug/shr-4610#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
